Table 1.
The basic characteristics of included studies in the meta-analysis
| Author | Year | Country | Cases | Tumor type | Clinical stage | Cut-off value | Outcome | OS | DFS/PFS/TTP | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| U/M | HR(95%CI) | U/M | HR(95%CI) | ||||||||
| Pedersen LM | 1996 | Denmark | 1115 | NSCLC+ SLCL | I-IV | 400 | OS | M | 4.24(1.50–12.72) | ||
| Cox G | 2000 | UK | 175 | NSCLC | I-IIIA | 320 | OS | M | 1.69(1.12–2.56) | ||
| Suzuki M | 2002 | Japan | 99 | NSCLC | I-IV | 231 | OS | M | 3.04(1.08–8.55) | ||
| Swinson DE | 2003 | United Kingdom | 175 | NSCLC | I-IIIA | 314 | OS | M | 1.64(1.13–2.39) | ||
| Bremnes RM | 2003 | Norway | 436 | SCLC | – | 150 | OS | M | 3.10(1.40–7.20) | ||
| Unsal E | 2004 | Turkey | 58 | NSCLC+ SLCL | I-IV | 400 | OS | M | 0.96(0.54–1.72) | ||
| Aoe K | 2004 | Japan | 611 | NSCLC+ SLCL | I-IV | 400 | OS | M | 1.29(1.02–1.64) | ||
| Prévost S | 2006 | Canada | 120 | NSCLC | Not Report | 340 | OS | M | 1.50(1.0–2.30) | ||
| Tomita M | 2008 | Japan | 240 | NSCLC | I-IV | 400 | OS | M | 1.46(1.01–2.01) | ||
| Gonzalez Barcala FJ | 2010 | Spain | 365 | NSCLC+ SCLC | I-IV | 258 | OS | M | 1.15(0.90–1.47) | ||
| Gonzalez Barcala FJ | 2010 | Spain | 294 | NSCLC+ SCLC | I-IV | 381 | OS | M | 1.09(0.82–1.46) | ||
| Luo J | 2012 | USA | 110 | NSCLC | I-IV | 300 | OS | M | 2.86(1.48–5.54) | ||
| Holgersson G | 2012 | Sweden | 823 | NSCLC | I-IV | 350 | OS | M | 1.35(1.12–1.62) | ||
| Yu D | 2013 | China | 510 | NSCLC | I-III | 300 | OS,DFS | M | 1.69(1.01–2.38) | M | 1.57(1.01–2.45) |
| Maráz A | 2013 | Hungary | 398 | NSCLC+ SLCL | I-IV | 400 | OS | M | 1.58(1.14–2.18) | ||
| Kim KH | 2014 | Korea | 854 | NSCLC | III-IV | 450 | OS | M | 1.51(1.14–2.00) | ||
| Kim M | 2014 | Korea | 199 | NSCLC | I-III | 400 | OS,DFS | M | 2.98(1.39–6.37) | M | 2.47(1.22–5.01) |
| Ji Y | 2014 | China | 234 | NSCLC | I | 300 | OS,DFS | M | 3.14(1.23–8.03) | M | 5.31(2.75–10.27) |
| Zhu JF | 2014 | China | 275 | NSCLC | IV | 300 | OS | M | 1.40(1.00–2.00) | ||
| Hong X | 2016 | China | 999 | SCLC | – | 300 | OS,PFS | M | 1.01(0.87–1.18) | M | 0.91(0.70–1.17) |
| Gotfrit J | 2016 | Canada | 223 | NSCLC | IIIB-IV | 400 | OS | M | 1.46(1.03–2.09) | ||
| Boddu P | 2016 | USA | 571 | NSCLC | I-IV | 450 | OS | M | 1.64(1.05–2.55) | ||
| Liu W | 2017 | China | 1120 | NSCLC | I-IIIA | 300 | OS,DFS | M | 1.15(0.96–1.39) | M | 1.17(0.97–1.40) |
| Wang YQ | 2017 | China | 134 | NSCLC | I-IIIA | 289 | OS,DFS | M | 2.28(1.43–3.62) | U | 1.63(1.01–2.64) |
| Holgersson G | 2017 | Sweden | 222 | NSCLC | III | 350 | OS | M | 1.66(1.12–2.48) | ||
| Holgersson G | 2017 | Sweden | 99 | NSCLC | IIIB-IV | 350 | OS | M | 1.25(0.71–2.22) | ||
| Cui MM | 2017 | China | 270 | NSCLC | I-III | Not Report | OS | M | 1.00(1.00–1.01) | ||
| Ohuchi M | 2017 | Japan | 146 | NSCLC+ SLCL | I-IV | 244 | OS | M | 1.88(1.13–3.13) | ||
| Mandrekar SJ | 2006 | Canada+ USA | 1053 | NSCLC | IIIB-IV | 375 | OS,TTP | U | 1.41(1.24–1.60) | U | 1.27(1.11–1.45) |
| Altiay G | 2007 | Turkey | 78 | NSCLC+ SLCL | III-IV | 400 | OS | U | 2.33(1.27–4.26) | ||
| Qiu MZ | 2010 | China | 430 | NSCLC | I-IV | 400 | OS | U | 1.09(0.60–1.98) | ||
| Liu HB | 2013 | China | 883 | NSCLC | I-IV | 300 | OS | U | 1.30(1.02–1.66) | ||
| Du G | 2013 | China | 258 | NSCLC | IIIA-IV | 400 | OS,PFS | U | 4.15(3.09–5.59) | U | 3.47(2.60–4.65) |
| Zhang T | 2014 | China | 400 | NSCLC | I-II | 190 | OS,DFS | U | 1.47(0.88–2.45) | U | 1.57(1.01–2.45) |
| Wu G | 2015 | China | 366 | NSCLC | III-IV | 117.5 | OS,PFS | U | 1.22(0.90–1.65) | U | 1.25(0.92–1.69) |
| Zhang H | 2015 | China | 1238 | NSCLC | I-IIIA | 300 | OS,DFS | U | 1.38(1.17–1.63) | U | 1.38(1.16–1.63) |
| Zhang W | 2015 | China | 308 | NSCLC | I-IV | 300 | OS | U | 1.67(1.23–2.27) | ||
| Gao L | 2017 | China | 546 | NSCLC | I-IIIA | 300 | OS,DFS | U | 1.72(1.35–2.19) | U | 1.70(1.33–2.17) |
| Li Y | 2014 | China | 126 | NSCLC | III-IV | 200 | PFS | M | 1.69(1.16–2.46) | ||
| Lee S | 2017 | Korea | 135 | NSCLC | IIIB-IV | 400 | OS | U | 1.49(0.80–2.78) | ||
NSCLC Non-small cell lung cancer, SCLC Small cell lung cancer, OS Overall survival, DFS Disease-free survival, PFS Progress-free survival, TTP Time to progress, HR Hazard ratio, CI Confidence interval M Multivariate analysis, U Univariate analysis